• Atripla (efavirenz / emtricitabine / tenofovir disoproxil fumarate) –  together with Bristol-Myers Squibb
• Complera (Eviplera) (emtricitabine / rilpivirine / tenofovir disoproxil fumarate) – together with Janssen
• Emtriva® (emtricitabine)
• Stribild™ (QUAD) (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate) –  together with Johnson&Johnson
• Truvada (emtricitabine / tenofovir disoproxil fumarate)
• Viread® (tenofovir disoproxil fumarate)

Information about the drug products is obtained from public sources or from company representatives and is intended solely for informing community representatives about the options currently available or in development. This information can under no circumstances be intepreted as advertising. The mentioning of any drug products does not mean EECA CAB prioritizes those products or, on the contrary, does not recommend them.

• GS-7340 – a prodrug of tenofovir, tenofovir alafenamid (TAF).
• GS-9137 – elvitegravir – integrase inhibitor.
• GS-9350 – cobicistat – a pharmacokinetic enhancer.
• Elvitegravir/cobicistat/emtricitabine/GS-7340 (TAF) – fixed dose combination (FDC).
• Darunavir/cobicistat/emtricitabine/GS-7340 (TAF) – fixed dose combination (FDC) – together with Janssen.
• Darunavir/cobicistat – fixed dose combination (FDC) – together with Janssen.
• Atazanavir/cobicistat – together with BMS.

Hepatitis C pipeline

• Nucleoside polymerase inhibitors
  • Sofosbuvir GS-7977 (once a day) – filed for registration in the United States
• Inhibitors of NS5A
  • Ledipasvir GS-5885 (once a day)
• Protease Inhibitors
  • GS-9256 (twice a day)
  • GS-9451 (once a day)
• Non-nucleoside polymerase inhibitors:
  • Tegobuvir (GS-9190) (twice a day)
• FDC
  • Sofosbuvir/Ledipasvir (once-daily), phase III